Medical Patent News

RSS

Arrayit receives patent certification from China

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces that on August 31st, 2009 the company received a patent certificate from the most populous country on the planet, the People's Republic of China. The patent covers Dr. Mark Schena's microarray methods of genotyping multiple patient samples, commonly referred to as Arrayit's "Variation Identification Platform™" (VIP) technology.

2 Sep 2009

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

A groundbreaking new treatment for obesity is to begin clinical trials in January. Madrona Ventures Inc., an American publicly listed company (OTCBB:MDRV), has acquired the treatment's European patent and the pending American patent application.

2 Sep 2009

LifeVantage granted third patent for Protandim

LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim’s® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.

2 Sep 2009

New patented cactus-based cigarettes launched by China Kangtai Cactus Biotech

China Kangtai Cactus Biotech Inc. (OTC Bulletin Board: CKGT), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based products in China, announced today that the company has successfully completed the trial production of cactus-based cigarettes and plans to launch two products in the forth quarter in 2009: (i) low nicotine and (ii) zero nicotine cigarettes.

2 Sep 2009

Oncolytics Biotech obtains 32nd U.S. Patent grant

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 32nd U.S. Patent, # 7,582,289, entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers.

1 Sep 2009

Four additional patents filed by Lifeline Biotechnologies for its First Warning System methods and technology

Lifeline Biotechnologies, Inc. (Pink Sheets:LLBO) today announced that it has filed four additional patents on its First Warning System™ methods and technology.

31 Aug 2009

USPTO awards two new patents to Nerites

Nerites Corporation announced Thursday that the United States Patent and Trademark Office (USPTO) issued two new patents covering the company’s technology. These “composition of matter” patents provide underlying intellectual property protection for surgical adhesives, films, and coatings. Nerites’ scientists create synthetic mimetics of the protein components used by marine mussels to stick to rocks under water.

28 Aug 2009

E-18 files for an international patent for its revolutionary self-sheathing medical safety syringe technology

E-18 Corp. (OTCBB:ETEN) today announced that its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), completed an international patent filing for its revolutionary self-sheathing medical safety syringe technology, opening substantial opportunities abroad.

27 Aug 2009

American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

American Scientific Resources, Inc. (Pink Sheets: ASFX) (the Company), today confirmed that it has signed a letter of intent to acquire the intellectual property to the Disintegrator home needle destruction device (NDD) (U.S. Patent No. 6,384,362 Patent Application No.: 09/500,504).

27 Aug 2009

HTDS provides access to USPTO documents related to its IP ownership rights

Hard to Treat Diseases (the "Company") (HTDS.PK) provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.

26 Aug 2009

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

BioDelivery Sciences International, Inc. today announced the issuance of United States Patent 7,579,019, which will provide additional patent exclusivity for both ONSOLIS and BDSI’s BEMA drug delivery technology platform until at least 2019.

26 Aug 2009

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

REGENERX BIOPHARMACEUTICALS, INC. (the “Company” or “RegeneRx”) announced today that it received a “Notice of Allowance” in Europe for its patent application: Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides.

25 Aug 2009

Milestone Scientific receives Notice of Allowance to use disposable hand piece for fluid administration

Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for Milestone's U.S. patent application directed to the use of its disposable hand piece for fluid administration.

25 Aug 2009

Osteologix announces receipt of Decision to Grant a Patent from JPO for NB S101 osteoporosis drug candidate

Osteologix, Inc. (OTCBB:OLGX) today announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for Application Number 2006-504379: "Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts". The patent claims cover the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the Company's lead osteoporosis drug candidate.

24 Aug 2009

Foamix's novel foam technology awarded US patent

Foamix Ltd., a leading developer of topical foams for dermatology and gynecology, announced today that it has been awarded US Patent #7575739 pertaining to its foam technology. The patent covers unique foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.

24 Aug 2009

ARIAD's petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and its co-plaintiffs today announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) has granted their petition for rehearing en banc and has vacated its April 2009 decision in the appeal that Eli Lilly and Co. filed in 2008. All twelve judges of the Federal Circuit will now rehear and reassess the merits of Lilly’s appeal.

24 Aug 2009

Biovail's patent infringement lawsuit against Cary Pharma may affect IntelGenx revenues

IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.

24 Aug 2009

Applied Nanoscience in joint venture agreement to produce disposable protective face mask

Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced it has reached a joint venture agreement to begin production on a disposable protective face mask with its Asia Pacific region partner. The protective mask will incorporate ANI's proprietary NanoFense™ technology, a U.S. patent pending antimicrobial nanoparticle formulation.

21 Aug 2009

RBC Life Sciences reports on patent-pending, nutritional supplement

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements and wound care/pain management products, announced today the debut of NeuroBright(TM), a patent-pending, nutritional supplement that improved test subjects' learning and memory skills by 50 percent during a recent laboratory trial.

20 Aug 2009

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

20 Aug 2009

Medical Patent News

Arrayit receives patent certification from China

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

LifeVantage granted third patent for Protandim

New patented cactus-based cigarettes launched by China Kangtai Cactus Biotech

Oncolytics Biotech obtains 32nd U.S. Patent grant

Four additional patents filed by Lifeline Biotechnologies for its First Warning System methods and technology

USPTO awards two new patents to Nerites

E-18 files for an international patent for its revolutionary self-sheathing medical safety syringe technology

American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

HTDS provides access to USPTO documents related to its IP ownership rights

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

Milestone Scientific receives Notice of Allowance to use disposable hand piece for fluid administration

Osteologix announces receipt of Decision to Grant a Patent from JPO for NB S101 osteoporosis drug candidate

Foamix's novel foam technology awarded US patent

ARIAD's petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit

Biovail's patent infringement lawsuit against Cary Pharma may affect IntelGenx revenues

Applied Nanoscience in joint venture agreement to produce disposable protective face mask

RBC Life Sciences reports on patent-pending, nutritional supplement

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News